ORIGINAL ARTICLE
Clinical significance of PON1 L55M, Q192R and I102V polymorphisms and their association with prostate cancer risk in Polish men
1
Department of Clinical Genetics, Faculty of Medicine, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Torun, Poland
2
Piotr Jarzemski
Submission date: 2019-07-23
Final revision date: 2020-01-10
Acceptance date: 2020-01-13
Publication date: 2020-05-20
Pol J Pathol 2020;71(1):55-61
KEYWORDS
TOPICS
ABSTRACT
We tested the association between PON1 L55M, Q192R and I102V polymorphic variants and PC risk in Polish men. DNA from 110 consecutive, newly diagnosed patients hospitalized because of PC and DNA from 110 men – volunteers, healthy at the time of the study. PCR-RFLP method. In our study the average age at PC diagnosis of 55MM genotype carriers from families fulfilling Hereditary Prostate Criteria (HPC) was statistically significantly lower (by 7 years) than the average age at the disease diagnosis of 55MM carriers from families without HPC (54.6 ±6.7 vs. 61.9 ±5.4, respectively, p = 0.03). The probability of 5-year survival for the 55MM carriers was 81.3%, compared to 95.7% for non-carriers (p = 0.08, tendency). This is the first study in Polish men evaluating the impact of PON1 genetic polymorphisms on prostate cancer development and its clinical course. PON1 55MM variant may be probably associated with younger age at PC onset in men from families with HPC and with a shorter survival. However, more extensive studies on a larger number of PC patients, possibly from various populations, are necessary to confirm, and extend our findings.
REFERENCES (30)
1.
Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2017. CA Cancer J Clin 2017; 67: 7-30.
2.
Li C, Long B, Qin X, et al. Cytochrome P1B1 (CYP1B1) polymorphisms and cancer risk: a meta-analysis of 52 studies. Toxicology 2015; 327: 77-86.
3.
Arpaci A, Görmüs U, Dalan B, et al. Investigation of PON1 192 and PON1 55 polymorphisms in ovarian cancer patients in Turkish population. In Vivo 2009; 23: 421-424.
4.
Wu J, Fang M, Zhou X, et al. Paraoxonase 1 gene polymorphisms are associated with an increased risk of breast cancer in a population of Chinese women. Oncotarget 2017; 8: 25362-25371.
5.
Wen Y, Huang Z, Zhang X, et al. Correlation between PON1 gene polymorphisms and breast cancer risk: a meta-analysis. Int J Clin Exp Med 2015; 8: 20343-20348.
6.
Hu P, Ma Y, Zhang L, et al. PON1 L55M polymorphism might contribute to the risk of cancer. Panminerva Med 2017; 59: 107-113.
7.
Chen L, Lu W, Fang L, et al. Association between L55M polymorphism in paraoxonase 1 and cancer risk: a meta-analysis based on 21 studies. Onco Targets Ther 2016; 9: 1151-1158.
8.
Stevens VL, Rodriguez C, Talbot JT, et al. Paraoxonase 1 (PON1) polymorphisms and prostate cancer in the CPS-II Nutrition Cohort. Prostate 2008; 68: 1336-1340.
9.
Wang H, Li L, Ding L, et al. Association of genetic polymorphisms in the paraoxonase 1 gene with the risk and prognosis of non-small cell lung cancer in Chinese Han population. J Investig Med 2012; 60: 592-597.
10.
Eom SY, Yim DH, Lee CH, et al. Interactions between paraoxonase 1 genetic polymorphisms and smoking and their effects on oxidative stress and lung cancer risk in a Korean population. PLoS One 2015; 10: e0119100.
11.
Fang DH, Fan CH, Ji Q, et al. Differential effects of paraoxonase 1 (PON1) polymorphisms on cancer risk: evidence from 25 published studies. Mol Biol Rep 2012; 39: 6801-6809.
12.
Aldonza MB, Son YS, Sung HJ, et al. Paraoxonase-1 (PON1) induces metastatic potential and apoptosis escape via its antioxidative function in lung cancer cells. Oncotarget 2017; 8: 42817-42835.
13.
Trachootham D, Lu W, Ogasawara MA, et al. Redox regulation of cell survival. Antioxid Redox Signal 2008; 10: 1343-1374.
14.
Iwanicka J, Iwanicki T, Niemiec P, et al. Relationship between rs854560 PON1 gene polymorphism and tobacco smoking with coronary artery disease. Dis Markers 2017; 2017: 1540949.
15.
Tomatir AG, Pehlivan S, Sahin HH, et al. Q192R and L55M polymorphisms of paraoxonase 1 gene in chronic myelogenous leukemia and chronic lymphocytic leukemia. Anticancer Res 2015; 35: 4807-4812.
16.
Matés JM, Pérez-Gómez C, Blanca M. Chemical and biological activity of free radical 'scavengers' in allergic diseases. Clin Chim Acta 2000; 296: 1-15.
17.
Lobo V, Patil A, Phatak A, et al. Free radicals, antioxidants and functional foods: Impact on human health. Pharmacogn Rev 2010; 4: 118-126.
18.
Manolescu BN, Busu C, Badita D, et al. Paraoxonase 1 - an update of the antioxidant properties of high-density lipoproteins. Maedica (Buchar) 2015; 10: 173-177.
19.
Kao YL, Donaghue K, Chan A, et al. A variant of paraoxonase (PON1) gene is associated with diabetic retinopathy in IDDM. J. Clin Endocrinol Metab 1998; 83: 2589-2592.
20.
El-Lebedy D, Kafoury M, Abd-El Haleem D, et al. Paraoxonase-1 gene Q192R and L55M polymorphisms and risk of cardiovascular disease in Egyptian patients with type 2 diabetes mellitus. J Diabetes Metab Disord 2014; 13: 124.
21.
Zielaskowska J, Olszewska-S³onina D. The polymorphism of paraoxonase and its effects in physiological and pathological processes. Adv Clin Exp Med 2006; 15: 1073-1078.
22.
Eras N, Tombak A, Tiftik N, et al. Association between PON1 L55M polymorphism and PON1 enzyme activity in patients with leukemia. Int J Hematol Oncol 2017; 1: 21-28.
23.
Mackness B, Mackness MI, Arrol S, et al. Effect of the molecular polymorphisms of human paraoxonase (PON1) on the rate of hydrolysis of paraoxon. Br J Pharmacol 1997; 122: 265-268.
24.
Shunmoogam N, Naidoo P, Chilton R. Paraoxonase (PON)-1: a brief overview on genetics, structure, polymorphisms and clinical relevance. Vasc Health Risk Manag 2018; 14: 137-143.
25.
Marchesani M, Hakkarainen A, Tuomainen TP, et al. New paraoxonase 1 polymorphism I102V and the risk of prostate cancer in Finnish men. J Natl Cancer Inst 2003; 95: 812-818.
26.
Carter BS, Bova GS, Beaty TH, et al. Hereditary prostate cancer: epidemiologic and clinical features. J Urol 1993; 150: 797-802.
27.
Cybulski C, Gliniewicz B, Sikorski A, et al. Hereditary prostate cancer: Clinical genetics of cancers 2018. Lubiñski J (ed). Print Group Sp. z o.o., Poland 2018; 179-192.
28.
Antognelli C, Mearini L, Talesa VN, et al. Clinical genetics of cancers. Prostate 2005; 63: 240-251.
29.
Zhang M, Xiong H, Fang L, et al. Paraoxonase 1 (PON1) Q192R gene polymorphism and cancer risk: A meta-analysis based on 30 publications. Asian Pac J Cancer Prev 2015; 16: 4457-4463.
30.
Chen L, Lu W, Fang L, et al. Association between L55M polymorphism in paraoxonase 1 and cancer risk: a meta-analysis based on 21 studies. J Onco Targets Ther 2016; 9: 1151-1158.
Share
RELATED ARTICLE
| eISSN: | 2084-9869 |
| ISSN: | 1233-9687 |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
